Partial Epilepsy Clinical Trial
Official title:
Contribution of Multimodal Imaging (MRI, PET, MEG) in Pre-surgical Evaluation of Drug-resistant Focal Epilepsy
Epilepsy is the most common chronic neurological disorder in the world, affecting more than
50 million people worldwide. Approximately 35% of patients with epilepsy are refractory to
all available antiepileptic drugs. Drug-resistant epilepsies are often partial or focal.
Patients with drug-resistant focal epilepsy suffer from an increased risk of death,
primarily due to seizure-related fatalities, in comparison with the general population. The
only therapeutic option for this form of epilepsy is the surgical removal of the region of
the brain responsible for seizures, called the epileptogenic zone (EZ). This requires the
precise localization of the EZ based on a comprehensive pre-surgical evaluation of patients.
Today the gold standard for localizing the EZ and validating a non-invasive technique for
localization of the EZ remains intracerebral stereo-EEG (stereo-electroencephalography or
SEEG) recordings of spontaneous seizures. The implementation strategy of the intracerebral
depth electrodes is guided by clinical and neuroimaging data, including anatomical Magnetic
Resonance Imaging (MRI), Positron Emission Tomography (PET) with FDG (fluoro-Deoxy-Glucose)
and MagnetoEncephaloGraphy (MEG). Although the contribution of each technique in the
pre-surgical localization of the EZ has already been shown, no wide-scale study has examined
the cumulative contribution of these three techniques.
The purpose of this study is (i) to evaluate rigorously the diagnostic value of multimodal imaging for non-invasive localization of the EZ and (ii) to better target the indications for intracerebral recordings (SEEG). ;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT00982787 -
Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy
|
Phase 2 | |
| Completed |
NCT00898560 -
Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive
|
Phase 1 | |
| Completed |
NCT01090934 -
Localizing the Epileptogenic Zone With High Resolution Electroencephalography
|
N/A | |
| Terminated |
NCT00391534 -
EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy
|
Phase 3 | |
| Terminated |
NCT01496612 -
Buspirone Therapy for Localized Epilepsy
|
Phase 2 | |
| Completed |
NCT00900237 -
Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine
|
Phase 1 | |
| Recruiting |
NCT04903314 -
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures
|
Phase 1 | |
| Completed |
NCT01373190 -
Thermographic Examination of Skin Temperatures in Individuals With Focal Onset Epilepsy
|
N/A | |
| Completed |
NCT00894478 -
Improving Lesion Detection in Children With Magnetic Resonance Imaging (MRI)-Negative Partial Epilepsy Using Diffusion Tensor Imaging
|
N/A | |
| Recruiting |
NCT03478852 -
Investigating Epilepsy: Screening and Evaluation
|
||
| Recruiting |
NCT01273129 -
Surgery as a Treatment for Medically Intractable Epilepsy
|
||
| Completed |
NCT00001666 -
Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy
|
N/A | |
| Completed |
NCT00001932 -
Serotonin Receptors in Seizure Disorders
|
N/A | |
| Completed |
NCT00908349 -
Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy
|
Phase 3 | |
| Completed |
NCT02076698 -
Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy
|
Phase 3 | |
| Completed |
NCT00706160 -
Language Mapping in Patients With Epilepsy
|
||
| Completed |
NCT01397968 -
Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures
|
Phase 2 | |
| Completed |
NCT01866111 -
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
|
Phase 2 | |
| Completed |
NCT00957047 -
Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy
|
Phase 3 | |
| Terminated |
NCT01281956 -
PRX-00023 Therapy in Localization-Related Epilepsy
|
Phase 2 |